Carta Healthcare, whose software program platform applies AI to structured and unstructured information to lower the time and prices for information abstraction, has acquired Realyze Intelligence, which applies related expertise to oncology.
Based in 2019, San Francisco-based Carta Healthcare stated it applies each synthetic intelligence and professional medical information abstractors to serve a variety of well being techniques nationwide, from standalone neighborhood hospitals to massive educational medical facilities. It lists Mass Basic Brigham, CommonSpirit and Grady as amongst its well being system clients.
Realyze Intelligence was shaped in 2020 as a portfolio firm of UPMC Enterprises, the innovation, commercialization and enterprise capital arm of UPMC. Its software program analyzes structured and unstructured information in digital well being information to determine excellent sufferers for medical trials and different analysis research. The corporate says its clinician-trained AI can assemble applicable cohorts in seconds as a substitute of the standard hours or days the method consumes when carried out manually. Realyze Intelligence is utilized by most cancers facilities and is a part of the Memorial Sloan Kettering Most cancers Heart Innovation Hub. The CancerX Accelerator Program additionally chosen Realyze Intelligence as a part of its inaugural program earlier this yr.
Phrases of the acquisition weren’t disclosed.
A Realyze Intelligence evaluation discovered that through the use of the software program, UPMC Hillman Most cancers Heart noticed seven occasions extra sufferers matched to trials and twice as many enrolled, in comparison with the identical timeframe with out utilizing the software program. “We imagine information is the one most essential ingredient to enhance healthcare,” stated Brent Dover, CEO of Carta Healthcare, in an announcement. “From medical trials to medical registries, clinicians face insurmountable quantities of knowledge ripe with helpful data to enhance care practices and affected person outcomes. We’re impressed by Realyze Intelligence’s shared skill to make use of clinician-trained AI and a human-in-the-loop method to maximise insights from medical information, for medical trials and most cancers registries.”
“Well being techniques and pharmaceutical corporations make investments billions yearly to determine and enroll sufferers for medical trials—a course of that isn’t solely expensive however labor-intensive and time-consuming,” stated Aaron Brauser, founder and CEO of Realyze Intelligence, in an announcement. “Excessive-quality, well timed information is crucial for precisely figuring out eligible sufferers, but a lot of it stays trapped in EHRs and different techniques. We’re excited to revolutionize medical trial matching and reuse the information to boost analysis, optimize care pathways and enhance affected person outcomes with Carta Healthcare.”
